Prometic Life Sciences Price Target Raised to C$2.80 at Paradigm Capital (PLI)
Posted by Pezhman Azimi on May 14th, 2014 //
Prometic Life Sciences (TSE:PLI) had its price objective raised by Paradigm Capital from C$2.25 to C$2.80 in a research report released on Monday morning, Analyst RN reports. Paradigm Capital currently has a buy rating on the stock.
Separately, analysts at Canaccord Genuity initiated coverage on shares of Prometic Life Sciences in a research note on Tuesday, February 25th. They set a buy rating and a C$2.00 price target on the stock.
Prometic Life Sciences (TSE:PLI) traded down 0.95% on Monday, hitting $1.04. 344,320 shares of the company’s stock traded hands. Prometic Life Sciences has a 1-year low of $0.315 and a 1-year high of $1.65. The stock has a 50-day moving average of $1.14 and a 200-day moving average of $1.12. The company’s market cap is $549.4 million.
ProMetic Life Sciences Inc (TSE:PLI) is a bio-pharmaceutical comnpany offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens, The Company focuses its activities in two segments: protein technologies and therapeutics.
To view Paradigm Capital’s full report, visit Paradigm Capital’s official website.